Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victoria Foy

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Nature Cancer|August 8, 2022
cfDNA methylome profiling for detection and subtyping of small cell lung cancersFrancesca Chemi, Simon P Pearce, Alexandra Clipson, et al.
Cell Reports|April 30, 2025
Functional characterization of the ATOH1 molecular subtype indicates a pro-metastatic role in small cell lung cancerAlessia Catozzi, Maria Peiris Pagès, Sam Humphrey, et al.
Therapeutic Advances in Medical Oncology|March 10, 2023
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapyPaula Jimenez-Fonseca, Victoria Foy, Sophie Raby, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Nature Cancer|August 8, 2022
cfDNA methylome profiling for detection and subtyping of small cell lung cancersFrancesca Chemi, Simon P Pearce, Alexandra Clipson, et al.
Cell Reports|April 30, 2025
Functional characterization of the ATOH1 molecular subtype indicates a pro-metastatic role in small cell lung cancerAlessia Catozzi, Maria Peiris Pagès, Sam Humphrey, et al.
Therapeutic Advances in Medical Oncology|March 10, 2023
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapyPaula Jimenez-Fonseca, Victoria Foy, Sophie Raby, et al.
Pageof 2